- Home
- AVB vs RPRX Comparison
AVB vs RPRX Comparison
Compare AVB & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVB | RPRX |
|---|---|---|
| Founded | 1978 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 19.5B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVB | RPRX |
|---|---|---|
| Price | $182.43 | $49.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $198.40 | $51.40 |
| AVG Volume (30 Days) | 828.1K | ★ 2.5M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.86% | 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.40 | 1.78 |
| Revenue | ★ $3,040,725,000.00 | $2,378,193,000.00 |
| Revenue This Year | $4.04 | $38.63 |
| Revenue Next Year | $5.03 | $4.73 |
| P/E Ratio | ★ $24.87 | $27.78 |
| Revenue Growth | 4.36 | ★ 5.06 |
| 52 Week Low | $160.10 | $31.97 |
| 52 Week High | $213.34 | $50.25 |
Technical Indicators
Market Signals| Indicator | AVB | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.33 | 61.72 |
| Support Level | $182.17 | $35.34 |
| Resistance Level | $186.77 | $50.08 |
| Average True Range (ATR) | 3.46 | 0.88 |
| MACD | 1.53 | -0.06 |
| Stochastic Oscillator | 80.06 | 66.92 |
Price Performance
Historical ComparisonAbout AVB AvalonBay Communities Inc.
AvalonBay Communities owns a portfolio of 296 apartment communities with more than 90,000 units and is developing 24 additional properties with approximately 8,600 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.